These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 16397522)
1. Population-based prevalence of CDKN2A mutations in Utah melanoma families. Eliason MJ; Larson AA; Florell SR; Zone JJ; Cannon-Albright LA; Samlowski WE; Leachman SA J Invest Dermatol; 2006 Mar; 126(3):660-6. PubMed ID: 16397522 [TBL] [Abstract][Full Text] [Related]
2. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834 [TBL] [Abstract][Full Text] [Related]
3. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411 [TBL] [Abstract][Full Text] [Related]
4. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021 [TBL] [Abstract][Full Text] [Related]
5. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381 [TBL] [Abstract][Full Text] [Related]
6. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127 [TBL] [Abstract][Full Text] [Related]
7. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ; Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902 [TBL] [Abstract][Full Text] [Related]
8. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas. Harinck F; Kluijt I; van der Stoep N; Oldenburg RA; Wagner A; Aalfs CM; Sijmons RH; Poley JW; Kuipers EJ; Fockens P; van Os TA; Bruno MJ J Med Genet; 2012 Jun; 49(6):362-5. PubMed ID: 22636603 [TBL] [Abstract][Full Text] [Related]
9. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Holland EA; Schmid H; Kefford RF; Mann GJ Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations. Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189 [TBL] [Abstract][Full Text] [Related]
11. Pancreatic carcinoma surveillance in patients with familial melanoma. Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390 [TBL] [Abstract][Full Text] [Related]
12. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535 [TBL] [Abstract][Full Text] [Related]
13. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641 [TBL] [Abstract][Full Text] [Related]
14. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LA; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; ; J Med Genet; 2007 Feb; 44(2):99-106. PubMed ID: 16905682 [TBL] [Abstract][Full Text] [Related]
15. Pediatric melanoma in melanoma-prone families. Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590 [TBL] [Abstract][Full Text] [Related]
16. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638 [TBL] [Abstract][Full Text] [Related]
17. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776 [TBL] [Abstract][Full Text] [Related]
18. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies. Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250 [TBL] [Abstract][Full Text] [Related]